Key Milestones
2026 and Beyond
- Establish the "Hong Kong Clinical Trial Digital Portal"
- Establish the "International Clinical Trial Academy"
- Launch the first batch of representative regional collaborative clinical trial projects through the “Greater Bay Area Clinical Trial Collaboration Platform”
- Establish and apply the real world data platform for the approval of innovative medical products
2025
- Establish the "Real-World Study and Application Centre" to support new drug development
-
Jointly establish the "GBA Clinical Trial Collaboration Platform" with the GBA International Clinical Trial Center in the Shenzhen Park
-
Move into the wet-laboratory enabled building in the Hong Kong-Shenzhen Innovation
-
Signed a Memorandum of Understanding (MoU) with HKUMed and CU Medicine on clinical trial collaboration
-
Signed a Memorandum of Understanding (MoU) with the international pharmaceutical company GSK and the local biopharma company ImmunoCure to promote cross-border real-world and clinical trial projects
2024
- Established at the Central Government-Aided Emergency Hospital, the temporary office and the biobank officially opens
-
2023
- The Chief Executive proposed the establishment of the Greater Bay Area International Clinical Trial Institute (GBAICTI) in the Policy Address
-
